[{"arm_notes": "", "treatment_id": null, "treatment_name": "FINLAY-FR-1 intervention (Experimental): Dose 10 \u00b5g of RBD+adjuvant; 0.5 mL by intramuscular route. Treatment scheme: 0-28 days. Presentation: Vial with single dose. FINLAY-FR-1 intervention (Experimental): Dose 20 \u00b5g of RBD+adjuvant; 0.5 mL by intramuscular route. Treatment scheme: 0-28 days. Presentation: Vial with single dose. VA-MENGOC-BC\u00ae intervention (Control): Dose of 0.5 mL by intramuscular route. Treatment scheme: 0-28 days. Presentation: Vial with single dose.In each intervention will be two age groups: 19-59 years and 60-80 years.;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;Meningococcal Vaccines;VA-MENGOC-BC\u00ae", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "1", "treatment_id": 781, "treatment_name": "Meningococcal vaccine", "treatment_type": "Non covid vaccine", "pharmacological_treatment": "Non covid vaccine"}, {"arm_notes": "1", "treatment_id": 514, "treatment_name": "Finlay-fr-1 anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "FINLAY-FR-1 intervention (Experimental): Dose 10 ug of RBD+adjuvant; 0.5 mL by intramuscular route. Treatment scheme: 0-28 days. Presentation: Vial with single dose. FINLAY-FR-1 intervention (Experimental): Dose 20 ug of RBD+adjuvant; 0.5 mL by intramuscular route. Treatment scheme: 0-28 days. Presentation: Vial with single dose. VA-MENGOC-BC(R) intervention (Control): Dose of 0.5 mL by intramuscular route. Treatment scheme: 0-28 days. Presentation: Vial with single dose. In each intervention will be two age groups: 19-59 years and 60-80 years.;Immunogenicity; Vaccine;VA-MENGOC-BC(R)", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]